Company Encyclopedia
View More
name
BGI Genomics
300676.SZ
BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic sequencing; and mass spectrometry services, such as proteomic services and biologics characterization services. It also provides diagnostics and precision medicine, such as COVID-19 solutions, partnership opportunities, infectious diseases, and oncology services.
1.556 T
300676.SZMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking64/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-8.39%D
    • Profit Margin-21.53%D
    • Gross Margin41.02%B
  • Growth ScoreE
    • Revenue YoY-7.87%D
    • Net Profit YoY-687.17%E
    • Total Assets YoY-7.40%D
    • Net Assets YoY-6.01%D
  • Cash ScoreD
    • Cash Flow Margin-464.38%E
    • OCF YoY-7.87%D
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreB
    • Gearing Ratio23.82%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    China's DNA sequencing market set to reach $3.1 billion by 2030 with a 21.5% CAGR growth; driven by government support and innovation.

    China's DNA sequencing market is projected to grow from $1.2 billion in 2025 to $3.1 billion by 2030, with a CAGR of 21.5%, according to BCC Research. This growth is fueled by government support, the Precision Medicine Plan, and rising demand for precision medicine and oncology genomics. Key players like BGI Genomics and Novogene are thriving, while AI advancements are transforming the industry. The report offers insights for stakeholders aiming to leverage opportunities in this expanding sector.

    Unusual Whales·
    SZ
    300676
    +0.20%
    Unusual Whales·
    SZ
    300676
    +0.20%

    BGI Genomics: The sample size for the colorectal cancer livelihood project has exceeded 400,000 cases

    On October 24th, BGI Genomics stated during an institutional research that as of the end of the third quarter of this year, the overall sample size of the colorectal cancer livelihood project exceeded 400,000 cases, with revenue approaching 100 million yuan. In the future, the company will accelerate its transformation from a "testing service" to a comprehensive model of "products + services + data," forming a dual-drive pattern of C-end + B-end

    Zhitong·
    SZ
    300676
    +0.20%
    Zhitong·
    SZ
    300676
    +0.20%

    BGI Genomics: The upgraded version of non-invasive prenatal testing has currently entered the priority review of the National Medical Products Administration

    BGI Genomics stated at the Q3 2025 earnings briefing that its upgraded non-invasive prenatal testing has entered the priority review of the National Medical Products Administration, which is expected to bring business growth to the company in the future. In addition, the company is actively laying out testing products for cardiovascular diseases, cognitive disorders, and degenerative diseases to address the trend of population aging and explore new growth points in the elderly health market

    Zhitong·
    SZ
    300676
    +0.20%
    Zhitong·
    SZ
    300676
    +0.20%

    BGI Genomics Widens Q3 Loss, Revenue Rises 9%

    BGI Genomics Widens Q3 Loss, Revenue Rises 9%

    marketscreener·
    SZ
    300676
    +0.20%
    marketscreener·
    SZ
    300676
    +0.20%

    Zotye Automobile Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025

    Zotye Automobile Co., Ltd reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 419.35 million compared to CNY 384.81 million a year ago. Net loss was CNY 222.64 million compared to CNY 332.93 million a year ago.Basic loss per share from continuing operations was CNY 0.04 compared to CNY 0.07 a year ago. Diluted loss per share from continuing operations was CNY 0.04 compared to CNY 0.07 a year ago.

    marketscreener·
    SZ
    000980
    -0.80%
    marketscreener·
    SZ
    000980
    -0.80%
    © 2025 Longbridge｜Disclaimer